Hadrien Chef

Hadrien works closely with many different types of clients in Belgium's thriving pharma and biotech landscape. From start-ups to multinationals, his advice helps client identify how to success and grow as a business.

An experienced corporate lawyer who specialises in mergers and acquisitions (M&A), venture capital, public offerings, corporate reorganisations, corporate and security law, and corporate finance, Hadrien is a Partner in Osborne Clarke’s Brussels corporate team. In this role, he advises on public and private M&As, and acts for clients on a wide variety of transactional matters and restructurings, including setting-up, financing, reorganising, acquiring, or liquidating business ventures, also providing litigation services in these areas.

Hadrien is constantly close to the cutting-edge of biotechnology medical diagnostics and medtech. For example, he has been advising OncoDNA, a cancer theranostic company and winner of the Biotech Award of Deloitte’s 2020 Technology Fast50 competition, for several years as they expand their business to support oncologists in treatment decisions for patients. Other clients active in biotech, medtech and medical diagnostics include Bone Therapeutics, Biosourcing, ImmunXperts, Auxin Surgery, Kitozyme and BepharBel Manufacturing.

Along with his colleagues in the Osborne Clarke life sciences team, he is an active member of the Biowin consortium and a presenter at Essenica/Agoria on digital transformation in the life sciences industry.

While an unquestioned specialist in the field of life sciences, Hadrien has significant expertise in other areas, including technology, media and communications, and transportation and automotive, again regularly advising on M&A transactions, joint ventures and investment schemes. His experience in these sectors was gained on the international stage, having worked as an Associate in Hong Kong in 2015, and carrying out a secondment at a leading provider of specialised transportation and logistics in 2014.